MGMT and glioblastoma: Additional miRNAs with prognostic value include miR‐181d, which represses the MGMT gene, hence functioning as a predictive biomarker of poor survival for glioblastoma patients upon TMZ treatment [112, 113] and miR‐182, which is associated with TMZ susceptibility and a more favourable prognosis [114].